SOD1 and amyotrophic lateral sclerosis: Several studies have noted that the expression of Gal-3 in the plasma [111] and cerebrospinal fluid [89] was increased in ALS patients and the ALS animal model SOD1(G93A), indicating that Gal-3 might be a candidate biomarker of ALS [112, 113].